Journal Article

New data highlighting the efficacy and safety outcomes of third‐generation EGFR‐TKI in NSCLC patients with rare EGFR mutations

Li, Fengtan, Zhang, Weisan, Gao, Wenyuan

2020

Overview

Because of the high heterogeneity and low incidence of rare mutations in EGFR, it has been difficult to evaluate the efficacy of EGFR‐TKIs in the treatment of NSCLC with rare EGFR mutations. The results indicated that osimertinib had a response rate comparable to other EGFR‐TKIs in patients with Gly719Xaa or Leu861Gln mutations. [...]in patients with Ser768Ile mutations, the response rate of osimertinib was better than the first‐generation EGFR‐TKIs. [...]there were some accompanying limitations of this study that are worth mentioning: (i) Instead of whole‐genome sequencing, the authors used a low sensitivity and small sequencing coverage method (PCR combined with direct sequencing) to detect EGFR mutations. [...]there are certain limitations in detecting EFGR mutations; (ii) in addition to patients receiving first‐line osimertinib therapy, this study also included patients receiving second‐ and third‐line osimertinib therapy.

• Publisher: John Wiley & Sons Australia, Ltd,John Wiley & Sons, Inc,Wiley
• Subject: Cancer therapies / Carcinoma, Non-Small-Cell Lung - drug therapy / Carcinoma, Non-Small-Cell Lung - genetics / Carcinoma, Non-Small-Cell Lung - pathology / Chemotherapy / Clinical trials / Epidermal growth factor / ErbB Receptors - genetics / Genetic aspects / Humans / Lung cancer / Lung cancer, Non-small cell / Lung Neoplasms - drug therapy / Lung Neoplasms - genetics / Lung Neoplasms - pathology / Metastasis / Mutation / Patient outcomes / Prognosis / Protein Kinase Inhibitors - therapeutic use / Response rates / Studies / Targeted cancer therapy